Canada markets closed

Moleculin Biotech, Inc. (MBRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.91+0.37 (+6.68%)
At close: 04:00PM EDT
5.83 -0.08 (-1.35%)
After hours: 07:49PM EDT

Moleculin Biotech, Inc.

5300 Memorial Drive
Suite 950
Houston, TX 77007
United States
713 300 5160
https://www.moleculin.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees18

Key Executives

NameTitlePayExercisedYear Born
Mr. Walter V. KlempFounder, Chairman, President & CEO894.54kN/A1960
Mr. Jonathan P. Foster CPAExecutive VP & CFO611.17kN/A1964
Dr. Donald H. Picker Ph.D.Chief Scientific Officer486.44kN/A1946
Dr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory BoardN/AN/AN/A
Dr. Robert C. Shepard FACP, M.D.Chief Medical Officer of AnnamycinN/AN/A1952
Dr. John Paul Waymack M.D., Sc.D.Senior Chief Medical OfficerN/AN/A1952
Dr. Sandra L. Silberman M.D., Ph.D.Chief Medical Officer of New ProductsN/AN/A1955
Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D.European Chief Medical OfficerN/AN/AN/A
Ms. Jacqueline NorthcutConsultant51.11kN/A1962
Mr. Louis Ploth Jr.Independent Advisor118.49kN/A1954
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Corporate Governance

Moleculin Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.